The technique, called qBiCo, is described in the open-access journal Epigenetics Communications. It is a five-plex, TaqMan probe-based quantitative PCR assay that amplifies both single-copy genes and repetitive elements in bisulfite-converted DNA, the modified molecule that nearly every methylation experiment actually measures. From a single reaction, qBiCo estimates four critical parameters: the concentration of converted DNA, its degree of fragmentation, the global conversion efficiency, and the presence of inhibitors that could derail PCR amplification downstream.

The need for such a tool stems from an awkward chemical compromise. Bisulfite conversion works by treating DNA with sodium bisulfite at low pH and elevated temperature, converting unmethylated cytosines into uracils while leaving methylated cytosines untouched. Subsequent PCR replaces the uracils with thymines, so methylation patterns appear as C-to-T sequence variants readable by microarrays, pyrosequencing or massively parallel sequencing. But the same aggressive conditions that perform the conversion also attack the DNA itself. Sodium bisulfite causes depyrimidination and generates abasic sites prone to strand breaks, meaning the treated molecule is fragmented, mostly single-stranded and contaminated with carryover chemicals. Choose gentler conditions and the conversion becomes incomplete, leading to overestimated methylation and misinterpreted data. Choose harsher conditions and the DNA shatters beyond use.

Despite these well-known hazards, most epigenetics researchers have relied on manufacturer promises of greater than 99 percent conversion efficiency, at least 80 percent recovery and eluted fragments up to 2,000 base pairs long. Existing assessment approaches have been piecemeal: Nanodrop spectrophotometry, Qubit fluorometry and Bioanalyzer fragment analysis were never designed for the peculiar, hybrid single- and double-stranded nature of bisulfite-converted DNA. Earlier targeted assays, such as one developed by Ehrich and colleagues, measured fragmentation at increasing incubation temperatures but said nothing about conversion efficiency, while single-locus approaches risked severe bias. None offered a global picture in one test.

The Rotterdam team, led by Athina Vidaki together with Faidra Karkala and colleagues, designed qBiCo around two carefully chosen target classes. A short fragment of the single-copy hTERT gene reports converted DNA concentration, while a longer fragment of the same gene provides a fragmentation index. Two assays target the genomic and converted versions of LINE1, a repetitive element that constitutes roughly 17 percent of the human genome, allowing conversion efficiency to be measured across hundreds of genomic copies rather than a single locus. Because each LINE1 probe interrogates five cytosines across approximately 180 to 200 genomic regions, the efficiency measure is far more representative than comparable systems, such as BisQuE, which relies on a single cytosine in one gene intron. A fifth assay, a spiked-in artificial fragment, acts as an internal positive control flagging PCR inhibition.

Because no reliable standard exists for quantifying converted DNA, the team built synthetic DNA fragments, or gBlocks, mimicking the exact sequences their assays produce, mixed in ratios that resemble natural human converted DNA. Validation showed PCR efficiencies between 90 and 99 percent, linear detection down to picogram quantities, and striking robustness: conversion efficiency readings held steady even in the presence of extremely high levels of the PCR inhibitor hematin. Only artificial DNA degradation, induced by even one minute of UV exposure, meaningfully disturbed the readings.

The real drama came when the researchers applied qBiCo to ten commercial bisulfite conversion kits across DNA inputs ranging from 200 nanograms down to 1 nanogram. Recovery of converted DNA ranged from a sobering 8.5 to 100 percent, and conversion efficiencies from 78 to 99.9 percent, a spread that flatly contradicts the universal promises on the packaging. One kit failed systematically, producing conversion rates as low as 2 percent. Others lost more than 70 percent of the input DNA, while a handful, notably kits from Diagenode, Sigma Aldrich and Qiagen, maintained conversion efficiency above 95 percent even at the lowest inputs. Fragmentation proved pervasive: even with the best-performing kit, the intact portion of DNA fragments at least 235 base pairs long was no more than 50 to 60 percent of the sample, and longer fragments became undetectable at 10-nanogram inputs.

These results echo and extend earlier warnings. A 2018 study by Kint and colleagues had already reported kit recoveries ranging from 26.6 to 88.3 percent using a cumbersome multi-method approach that consumed precious sample. Even the inventor of bisulfite conversion, Hikoya Hayatsu, cautioned in 2008 that available methylation data needed careful re-examination and that a scientifically sound, assured methodology should be established as soon as possible. The qBiCo team argues that the field has, in effect, been running on assumption, and that no bisulfite-converted-DNA-specific method existed until now to hold the process accountable.

Determined to turn the assay into a practical tool, the researchers built an improved prototype, qBiCo-v2. They replaced the weakest assay, a long hTERT fragment, with a 222-base-pair target from the TPT1 gene, halved the reaction volume to 10 microliters, refined the synthetic standard using data from sixteen different conversion kits, and developed a semi-automated spreadsheet pipeline that calculates all four indices directly from raw qPCR output. Crucially, they transferred the method to six qPCR platforms from three major manufacturers, BioRad, Thermo Fisher Scientific and Qiagen, and validated it on each, finding comparable quantification cycles across instruments and establishing a detection limit of 150 picograms of input DNA.

The implications reach well beyond the bench. DNA methylation biomarkers are moving toward clinical implementation in cancer detection, ageing research and forensic science, settings where standardization is paramount and where scarce or degraded samples, such as cell-free tumor DNA or crime-scene traces, make every molecule count. The authors call on epigenetics researchers to shift from assuming their conversion kits work to measuring them empirically, integrating qBiCo as a routine quality-control step regardless of the downstream analysis. If they succeed, a reaction that has quietly shaped two decades of epigenetic data may finally get the scrutiny it has always needed, and the methylation maps of the future could rest on far firmer ground.

Subject of Research: Quality control of bisulfite-converted DNA methylation analysis using quantitative PCR

Article Title: qBiCo: a method to assess global DNA conversion performance in epigenetics via single-copy genes and repetitive elements

Article References: Karkala, F., Simons, R. B., Claessens, F., Kalamara, V., Kayser, M., & Vidaki, A. (2025). qBiCo: a method to assess global DNA conversion performance in epigenetics via single-copy genes and repetitive elements. Epigenetics Communications, 5(1), Article 2. https://doi.org/10.1186/s43682-025-00033-3

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00033-3

Keywords: DNA methylation, bisulfite conversion, epigenetics, qPCR, quality control, LINE1, hTERT, DNA fragmentation, biomarkers, forensics, kit validation, standardization

A research team at Sun Yat-sen University in Guangzhou now reports a solution that could reshape how lung immunology is done. In a study published in Advanced Biotechnology, the researchers describe an immortalized mouse alveolar macrophage cell line, created not by introducing cancer-causing oncogenes but by switching on telomerase, the enzyme that naturally maintains the protective caps at the ends of chromosomes. The resulting cells, named iAMs, divide indefinitely yet, according to the team’s detailed molecular and functional profiling, retain an unmistakably primary-like identity.

The motivation is easy to appreciate. Harvesting primary alveolar macrophages requires flushing the airways of experimental animals, a procedure that yields only 200,000 to 500,000 cells per mouse. That quantity is quickly consumed by basic characterization experiments, leaving little material for the high-throughput screens, genetic manipulations, and replication studies on which modern biomedical science depends. Worse still, the cells rapidly lose their defining traits once removed from the alveolar environment, senescing quickly in culture dishes.

Existing cell lines have not filled the gap convincingly. The AMJ2-C8 and AMJ2-C11 lines, created decades ago by v-raf and v-myc oncogene transduction, respond abnormally to bacterial products such as lipopolysaccharide and muramyl dipeptide and fail to secrete adequate amounts of the inflammatory cytokines IL-1 and TNF. The widely used MH-S line, immortalized with SV40 T antigen, lacks Siglec-F, one of the most recognizable surface markers of the mouse alveolar macrophage, and does not express the receptor CD116, leaving it deaf to GM-CSF, a growth factor central to alveolar macrophage biology, and blunted in its responses to bacterial stimulation.

The Sun Yat-sen team chose a gentler strategy. Human telomerase reverse transcriptase, or hTERT, has previously been used to immortalize a range of primary cell types without dragging them toward a cancer-like state, because it extends replicative lifespan rather than rewiring growth-control pathways. The researchers packaged hTERT into a lentiviral vector and delivered it to primary alveolar macrophages isolated from C57BL/6 mice by bronchoalveolar lavage. After selection with puromycin and isolation of single-cell clones, four stable lines emerged, all confirmed free of mycoplasma contamination and indistinguishable from one another in morphology, marker expression, and growth. Short tandem repeat profiling verified that the final line traced back to the original primary cells, and all subsequent work used cells between passages 1 and 12.

The proliferative leap is dramatic. Where primary alveolar macrophages stagnate, the iAMs double roughly every 12 hours, nearly all of them staining positive for the proliferation marker Ki67 and incorporating the DNA precursor EdU at rates far above those of their primary counterparts. Crucially, this vigor did not come at the cost of appearance. Under bright-field and transmission electron microscopy, the cells resemble freshly isolated alveolar macrophages, with similar Giemsa and Oil Red O staining patterns. Scanning electron microscopy revealed one subtle difference: the immortalized cells keep the spherical shape of their primary ancestors but extend fewer pseudopodia, the membrane protrusions macrophages use to crawl and engulf.

Transcriptionally, the resemblance holds up under rigorous scrutiny. Bulk RNA sequencing compared iAMs with primary alveolar macrophages, with AM-like cells differentiated from bone marrow precursors using GM-CSF, TGF-beta and rosiglitazone, and with bone marrow-derived macrophages, the workhorse surrogate in many labs. Principal component analysis placed the iAMs closest to primary alveolar macrophages, and pairwise correlation and hierarchical clustering confirmed the same picture. Out of the whole transcriptome, differential expression analysis flagged 2,953 genes changing by at least twofold between iAMs and primary cells, concentrated in immune signaling and metabolic pathways. Functional module scoring showed the immortalized cells mirroring primary cells across lysosome, phagocytosis, oxidative phosphorylation, chemotaxis and M2 polarization programs, with antigen presentation scoring somewhat higher in the immortalized line.

Surface phenotype and function tracked the transcriptome. Flow cytometry confirmed the canonical alveolar macrophage signature of intermediate F4/80, low CD11b, high Siglec-F and high CD11c, and quantitative PCR validated expression of AM-specific, alternative activation and self-renewal genes at levels comparable to primary cells. In functional assays, the iAMs actually outperformed primary cells in some respects: they engulfed fluorescently labeled E. coli more avidly than either primary alveolar macrophages or AM-like cells, and they migrated more efficiently toward Pseudomonas aeruginosa in Transwell chemotaxis chambers. When stimulated with lipopolysaccharide, lipoteichoic acid, or heat-inactivated Pseudomonas, they mounted inflammatory cytokine responses, including Il1a, Il1b, Il6, Ccl2 and Tnfa, closely matching those of primary cells.

The most demanding test came in living animals. The team depleted resident alveolar macrophages in mice with clodronate liposomes, achieving roughly 95.7 percent depletion, and then transferred iAMs directly into the airways before challenging the animals with Pseudomonas aeruginosa. The transferred cells engrafted stably in the alveolar space and, tracked with the fluorescent dye PKH26, were still detectable 14 days later, by which point they accounted for more than half of the CD11c-positive population. Mice lacking alveolar macrophages developed severe lung injury, with blood-tinged and turbid lavage fluid, elevated protein levels, massive neutrophil infiltration and high bacterial burdens. Reconstitution with iAMs significantly eased every one of these pathological features, restoring bacterial clearance and restraining neutrophil recruitment, evidence that the immortalized cells can genuinely stand in for their natural counterparts in pulmonary host defense.

The authors are candid about the model’s limits. Immortalization and long-term culture can introduce genetic or epigenetic drift and clonal selection, and the enhanced antigen-presenting capacity and reduced pseudopod formation show the cells are not perfect copies of freshly isolated macrophages. The team recommends working within the validated passage range and monitoring key markers and functions, with critical findings confirmed in primary cells when maximum fidelity is required. Even with those caveats, the resource fills a conspicuous void. Bone marrow-derived macrophages and monocyte-derived macrophages differ fundamentally from tissue-resident macrophages in developmental origin, transcriptional wiring and functional repertoire, and oncogene-transformed lines carry distortions of their own. A telomerase-immortalized line that preserves the alveolar macrophage identity opens the door to high-throughput drug screening, CRISPR-based mechanistic dissection and reproducible functional assays that were previously impractical, and it promises to accelerate research on lung immunology, host defense and pulmonary homeostasis for years to come.

Subject of Research: Generation and characterization of an hTERT-immortalized mouse alveolar macrophage cell line

Article Title: hTERT-immortalized mouse alveolar macrophages retain primary-like transcriptional and functional programs

Article References: hTERT-immortalized mouse alveolar macrophages retain primary-like transcriptional and functional programs. (n.d.). https://doi.org/10.1007/s44307-026-00130-x

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00130-x

Keywords: alveolar macrophages, hTERT, cell immortalization, telomerase, lung immunology, phagocytosis, Pseudomonas aeruginosa, RNA sequencing, host defense, macrophage cell line, pulmonary homeostasis, GM-CSF